Q-omics provides the consensus-scored LCN10 profile across patient tissues and cancer cell-line models. LCN10 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, LCN10 is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, LCN10 RNA expression shows 13,891 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LUAD, BLCA, and UVM as cancer lineages where LCN10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LCN10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LCN10 survival associations across molecular data types. LCN10 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LCN10 RNA expression–survival associations across cancer types. High LCN10 expression shows unfavorable associations in LAML and MESO, but favorable associations in LUAD, HNSC, PAAD and LIHC. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for LCN10 RNA expression.
This table summarizes LCN10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for LCN10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LCN10 shows lower tumor expression in BLCA, COAD, KIRP, LUAD, UCEC and LUSC. The BLCA box plot shows higher LCN10 RNA expression in normal versus tumor tissue (log2 FC = −0.720, t-test p < 0.001).
This table shows molecular features associated with LCN10 in patient tissues and cancer cell lines. In patient samples, LCN10 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, LCN10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
